ABSTRACT Background: Observational studies have indicated that differences in the composition of human milk and infant formula yield benefits in cognitive development and early growth for breastfed infants Objective: The objective was to test the hypothesis that feeding an infant formula with reduced energy and protein densities and supplemented with bovine milk fat globule membrane (MFGM) reduces differences in cognitive development and early growth between formula-fed and breastfed infants. Design: In a prospective, double-blind, randomized controlled trial, 160 infants ,2 mo of age were randomly assigned to be fed an MFGM-supplemented, low-energy, low-protein experimental formula (EF) or a standard formula (SF) until 6 mo of age. The energy and protein contents of the EF and SF were 60 and 66 kcal/100 mL and 1.20 and 1.27 g/100 mL, respectively. A breastfed reference (BFR) group consisted of 80 infants. Results: At 12 mo of age, the cognitive score (mean 6 SD) on testing with the Bayley Scales of Infant and Toddler Development, Third Edition, was significantly higher in the EF group than in the SF group (105.8 6 9.2 compared with 101.8 6 8.0; P = 0.008) but was not significantly different from that in the BFR group (106.4 6 9.5; P = 0.73). The EF group ingested larger volumes of formula than did the SF group (864 6 174 compared with 797 6 165 mL/d; P = 0.022), fully compensating for the lower energy density. No significant differences in linear growth, weight gain, body mass index, percentage body fat, or head circumference were found between the EF and SF groups. Conclusions: MFGM supplementation to infant formula narrows the gap in cognitive development between breastfed and formula-fed infants. Between 2 and 6 mo of age, formula-fed term infants have the capacity to upregulate their ingested volumes when the energy density of formula is reduced from 66 to 60 kcal/100 mL. This trial was registered at clinicaltrials.gov as NCT00624689.
INTRODUCTION
According to the WHO, human milk is the optimal source of nutrition during the first 6 mo of life for healthy growth and the development of infants (1) . Observational studies of infant cognitive function have shown an advantage for breastfed infants over formula-fed infants, even after control for socioeconomic factors. This indicates that human milk components needed for optimal neurodevelopment are lacking for infant formula (2)-a finding further supported by one cluster-randomized breastfeeding promotion study (3) . The milk fat globule membrane (MFGM) 4 has gained interest as a biologically active milk fraction with potential positive health effects (4) . Several individual components of the MFGM have been shown to be essential for brain development and are also known to be present at lower concentrations in infant formulas than in human milk, eg, sialic acid (5, 6) , gangliosides (7) (8) (9) , sphingomyelin (10) (11) (12) , choline (10, 13, 14) , and cholesterol (15) (16) (17) .
Compared with breastfed infants, formula-fed infants usually have higher weight gains between 3 and 12 mo of age (18) (19) (20) , and this has been suggested to cause some of the observed longterm disadvantages for formula-fed infants, eg, a higher risk of obesity (21, 22) , hypertension (23, 24) , type 2 diabetes (25, 26) , and type 1 diabetes (27) . The considerably higher protein intake in formula-fed infants is an important reason for this difference in growth (28) , and, even after the trend of lowering the protein content of infant formulas during the past decades, the protein content is still 20-30% higher than in human milk, often resulting in a 40-50% higher protein intake in formula-fed than in breastfed infants (29, 30) . Whether a lower energy density of infant formula is safe and affects growth is still an open question. The energy density of breast milk is variable (31) and impossible to mimic in an infant formula. Virtually all currently available infant formulas have an energy density of 67 kcal/100 mL, based on the assumption that this level equals the average energy content of term human milk. With some allowance for variation, different regulations state a minimum energy density of 60 to 67 kcal/100 mL (32) (33) (34) (35) (36) . However, several studies suggest that the metabolizable energy of human milk is possibly overestimated by 10-30%; hence, considerably lower than in infant formulas (37) (38) (39) . Furthermore, formula-feeding and bottlefeeding have been associated with a reduced self-regulation of energy intake (40, 41) .
The current study was a randomized controlled trial with the aim to evaluate health effects on infants fed an experimental formula (EF) with a reduced energy and protein content combined with supplementation with a bovine MFGM fraction. Primary outcomes were cognitive level at 12 mo and weight at 6 mo. Our main hypothesis was 2-tailed: 1) that the MFGMsupplemented EF would result in enhanced neurodevelopment and 2) that the infants receiving a low-energy, low-protein EF would have less weight gain than those receiving standard formula (SF).
SUBJECTS AND METHODS

Inclusion
From March 2008 to February 2012, 160 formula-fed infants (80 girls and 80 boys) and a breastfed reference (BFR) group with 80 infants (40 girls and 40 boys), all born at Umeå University Hospital, Umeå, Sweden, were recruited after inviting parents by telephone. Inclusion criteria were ,2 mo of age, gestational age at birth 37-42 wk, birth weight 2500-4500 g, absence of chronic illness, and exclusive formula feeding, or, for the BFR group, exclusive breastfeeding at inclusion and the mother s intention to exclusively breastfeed until 6 mo. Recommendations of feeding only small amounts (taste portions) of complementary foods between 4 and 6 mo of age were given to all parents. This study was approved by the Regional Ethical Review Board in Umeå. Complete oral and written information about the study was given to the parents/caregivers, and written consent was obtained from the parents or caregivers of all infants before inclusion.
Randomization and blinding
Formula-fed infants were stratified for sex and randomly assigned, by using a computerized randomization tool in blocks of 8, to receive a low-energy, low-protein MFGM-supplemented EF or SF from inclusion until 6 mo of age. Twins were jointly randomly assigned to the same intervention group. The intervention was blinded both to parents and staff until all infants had finished the intervention. Powdered formula was distributed to families together with preparation instructions in identical boxes marked with a code number, prepared at the manufacturing site before sending them to the study site.
Formula composition
BabySemp 1 (Semper AB) was used as the SF, and the EF was modified from this formula. The macronutrient and fatty acid compositions of the formulas are shown in Table 1 . Amino acid contents were calculated from the protein composition ( Table  2) . The EF was supplemented with a bovine MFGM fraction (Lacprodan MFGM-10; Arla Foods Ingredients). MFGM proteins constituted 4% (wt:wt) of the total protein content in the EF.
Assessment of cognitive function
At 12 mo of age, testing with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) (42) was performed. The Bayley-III tests were performed by 3 trained psychologist students who were supervised by one senior psychologist. All tests were videotaped and re-evaluated if there were any uncertainties.
Assessment of growth
Visits were made at baseline (,2 mo) and at 4, 6, and 12 mo of age. At each visit, weight (Seca 757; Seca), length (Seca 416; (43, 44) . Maternal and paternal weight and height were measured at one visit, and maternal prepregnancy weight was self-reported.
Blood samples and analyses
At each visit, venous blood samples were drawn .2 h after the latest meal. Plasma insulin was analyzed immediately, and blood urea nitrogen (BUN) was analyzed in frozen plasma in 3 batches by using standard techniques. From each group (EF, SF, and BFR), frozen plasma samples from 20 randomly selected infants (10 girls and 10 boys) were analyzed for the plasma amino acid pattern.
Dietary intake
Parents were asked to complete a 3-d food diary every month from inclusion until 6 mo of age to assess intakes of formula and any complementary foods. Volumes of each formula meal (EF and SF groups) and volume or weight of all complementary foods (EF, SF, and BFR groups) were measured and recorded by the parents using their own personal household measures and kitchen utilities. Macronutrient and energy intakes were calculated from the Swedish National Food Agency Database in combination with data from baby food manufacturers. Parents whose infants' intervention or breastfeeding was interrupted before 6 mo of age were asked to remain in the study for follow-up on an intent-totreat basis.
Statistical analysis
A prestudy power analysis showed that a sample size of 63 in each group was needed to detect a difference of 0.5 SD in the primary outcomes Bayley-III score and weight-for-age, with 80% power at the significance level of 0.05. The expected dropout rate was 25%; hence, 80 infants were included in each group. All analyses are presented on an intent-to-treat basis, ie, cases were included in the analysis irrespective of compliance with the intervention, except for data on formula intake that are presented per protocol. Cases with missing outcome data were excluded from the analyses. Statistical calculations were made by using IBM SPSS Statistics Version 19 (IBM 1989 (IBM , 2010 . Comparisons of proportions were made by using a chi-square test or, when the expected count in any cell was ,5, by Fisher's exact test. Comparisons of means were made by independent-samples t test, after being checked for normal distribution. Variables that were not normally distributed were log transformed before the calculations were made and transformed back for presentation as geometric means and 95% CIs. Longitudinal analyses of growth outcomes were made by a linear mixed model. Differences in concentrations of amino acids were compensated for multiple comparisons by Bonferroni post hoc test.
Relevant covariates were adjusted for in a multivariate model and presented as adjusted P values. For cognitive, motor, and verbal scores, the multivariate model included psychosocial background variables (maternal and paternal age, years of education, and smoking). For growth outcomes and blood analyses, the multivariate model in comparisons between the EF and SF groups included maternal weight gain during pregnancy, gestational diabetes, and maternal and paternal BMI, smoking, and chronic disease. For data on formula intake, baseline z scores for weight and length were added to the model. For growth outcomes and blood analyses, only unadjusted values are presented in comparisons with the BFR group.
RESULTS
Background characteristics, compliance, and dropouts
Background characteristics are shown in Table 3 . Rates of dropout and noncompliance are shown in Figure 1 . Of the infants in the BFR group, 72 of 73 (99%) were partially or exclusively breastfed at 4 mo of age, 64 of 72 (89%) were partially or exclusively breastfed at 6 mo of age, and 57 of 72 (79%) had no intake of formula until 6 mo of age.
Cognitive, motor, and verbal scores
Successful Bayley-III testing was performed at 12 mo of age in 71 of 73 (97%), 64 of 68 (94%), and 70 of 72 (97%) of the infants in the EF, SF, and BFR groups, respectively. Of the 8 infants not included in the analysis, 7 did not turn up for testing, and 1 infant did not cooperate in the testing situation and was not possible to assess. The cognitive score was 4.0 (95% CI: 1.1, 7.0) points higher in the EF group than in the SF group ( Table 4) . No significant differences in the motor or verbal domains were found between the EF and SF groups. The BFR group performed significantly better in the cognitive domain than did the SF group, but not compared with the EF group. Furthermore, mainly because of enhanced performance in the receptive verbal subscale, the BFR group performed better in the verbal domain than did both formula-fed groups, even after adjustment for psychosocial background variables (Table 4) .
Energy and macronutrient intakes
Of the infants who completed the intervention to 6 mo of age, data on food intakes were available from 135 of 142 (95%). During the intervention period between 2 and 6 mo of age, the mean (6SD) daily intake of study formula was larger in the EF group than in the SF group (876 6 148 compared with 810 6 146 mL/d; P = 0.010, adjusted P = 0.018), which resulted in virtually the same mean (6SD) energy and protein intakes from formula in the EF and SF groups: 525 6 89 compared with 535 6 96 kcal/d (P = 0.55, adjusted P = 0.63) and 10.5 6 1.8 compared with 10.3 6 1.9 g/d (P = 0.48, adjusted P = 0.49), respectively. In contrast, mean (6SD) fat and carbohydrate intakes from formula differed between the EF and SF groups: 30.6 6 5.2 compared with 28.4 6 5.1 g/d (P = 0.010, adjusted P = 0.018) and 52.5 6 8.9 compared with 60.0 6 10.8 g/d (P , 0.001, adjusted P , 0.001), respectively. From 4 mo of age, complementary foods were introduced to most of the infants on their parents' initiative. When data on intakes of complementary foods were added, there were still no significant mean (6SD) differences in energy or protein intakes between 4 and 6 mo of age between the EF and SF groups: 604 6 82 compared with 628 6 106 kcal/d (P = 0.14, adjusted P = 0.15) and 12.4 6 1.8 compared with 12.6 6 2.4 g/d (P = 0.46, adjusted P = 0.58), respectively. All results on energy and macronutrient intakes with regard to differences between the 2 intervention groups remained in a per-protocol analysis (excluding infants who discontinued the intervention before 6 mo of age). In the univariate model, but not in the multivariate model, the mean (6SD) formula meal size between 2 and 6 mo of age was larger in the EF group than in the SF group: 166 6 34 compared with 154 6 34 mL/meal (P = 0.032, adjusted P = 0.12). Mean meal sizes for each month of age during the intervention are shown in Figure 2 . The mean (6SD) number of daily meals between 2 and 6 mo of age did not differ significantly between the EF and SF groups: 5.7 6 1.1 compared with 5.8 6 1.2 meals/d (P = 0.59, adjusted P = 0.86).
Growth and protein markers
No significant interaction was found between randomization groups (EF compared with SF) and time on z scores for weight (P = 0.88), length (P = 0.76), BMI (P = 0.92), or head circumference (P = 0.51) from baseline to 12 mo of age. Adding maternal and paternal BMI, smoking and chronic disease, maternal weight gain during pregnancy, and gestational diabetes to the model did not change the results. When groups were divided into BFR compared with formula-fed groups (EF + SF), significant interactions were found between group and time on z scores for weight (P = 0.025) and length (P = 0.003). Growth 4 Most common diagnoses for maternal and paternal chronic disease: asthma/allergy (n = 37), endocrine disease including diabetes (n = 15), and inflammatory disease (n = 10).
5 Most common diagnoses for disease before inclusion: respiratory tract infection (n = 8), neonatal hypoglycemia (n = 6), neonatal respiratory distress (n = 4), and neonatal infection (n = 3). FIGURE 1. Dropout rates and compliance with intervention in the EF and SF groups and dropout rates for the BFR group. The most common causes of dropout were "no cause given" or "moved from study site" (n = 12) and gastrointestinal symptoms (n = 6). The most common causes of discontinued intervention were cow milk allergy (n = 3) and gastrointestinal symptoms (n = 2). BFR, breastfed reference; EF, experimental formula; SF, standard formula; PP, per protocol.
velocity (mean DSDS 6 SD) was faster in the formula-fed groups (EF + SF) than in the BFR group for weight and length between inclusion and 6 mo of age [0.41 6 0.74 compared with 0.03 6 0.63 (P , 0.001) and 0.36 6 0.63 compared with 20.12 6 0.70 (P , 0.001), respectively], but not between 6 and 12 mo of age [0.33 6 0.42 compared with 0.24 6 0.53 (P = 0.18) and 0.03 6 0.48 compared with 20.10 6 0.52 (P = 0.077), respectively]. No difference in cross-sectional z scores were found for weight, length, head circumference, or BMI between the EF and SF groups or between the formula-fed groups (EF + SF) and the BFR group at 4, 6, and 12 mo (Figure 3) . Furthermore, no differences in percentage body fat were found at baseline or 4 mo ( Table 5 ). No differences in fasting plasma insulin or BUN were found between the EF and SF group; however, compared with the BFR group, the formulafed infants had higher plasma insulin concentrations at baseline and 4 and 6 mo and higher BUN at baseline and 6 mo ( Table 5 ). The concentrations of plasma amino acids are shown in Table 6 . DISCUSSION We found that infants fed an MFGM-supplemented EF performed better on cognitive testing at 12 mo than did infants fed SF, and at a level not significantly different from the BFR group. The size of the difference in cognitive scores between the EF and SF groups-4.0 (95% CI: 1.1, 7.0) points-is well in line with the calculated difference in cognitive function between normalbirth-weight formula-fed and breastfed infants of 2.66 (95% CI: 2.15, 3.17) points after adjustment for socioeconomic confounders in the meta-analysis of observational studies by Anderson et al (2) .
To our knowledge, this was the first randomized controlled trial that has shown such a large positive effect of any supplementation to infant formula on cognitive function measured with the Bayley Scales of Infant Development test in term infants. The study was powered to detect a difference of 0.5 SD in the main outcome-Bayley-III score at 12 mo. Nonetheless, the mean difference between the groups of 4.0 points (0.44 SD) was statistically significant as a result of the low dropout rate and the narrow distribution in our population. The SD of the cognitive score in the current study was 9.1 points compared with the expected SD of 15.0 (42). The narrow distribution, a phenomenon also found in other studies of cognition in infancy (45, 46) , was probably a result of a selected healthy population with risk infants excluded in combination with few examiners compared with the Bayley normative sample.
The MFGM fraction has historically been discarded with the milk fat in the manufacturing of infant formula, and its functional role in human milk has not been clear. However, MFGM contains several components that are essential for brain development, and our interpretation is that MFGM-supplementation enhanced cognitive development in the formula-fed infants. We speculate that this could be a result of one single responsible factor [eg, sialic acid; 5, 6), gangliosides (7-9), sphingomyelin (10-12), choline (10, 13, 14) or cholesterol (15) (16) (17) ], a combination of 2 or several factors, or possibly different limiting factors in different infants. Supplementation with bovine MFGM to infants ,6 mo of age has never been studied before, but studies in older infants and children have shown a beneficial effect of bovine MFGM-supplementation to complementary food at 6-11 mo of age on diarrhea (47) and beneficial effects of bovine MFGMformula to preschool children on febrile episodes and behavioral problems (48) . Furthermore, our results support a study that showed that infants fed a formula supplemented with complex lipids containing gangliosides had higher scores on hand and eye coordination, performance intelligence quotient, and general intelligence quotient on the Griffiths Mental Development Scale at 6 mo of age than did infants fed an unsupplemented formula (9) .
Infants fed the EF fully compensated for the reduced energy and protein densities and showed a growth pattern not different from that of infants fed the SF. This did not confirm our original hypothesis that infants fed the EF would gain less weight. The precise self-regulation of the ingested formula volume shown by the EF group was unexpected because previous studies have shown that formula-feeding is associated with a reduced level of FIGURE 3. Mean (95% CI) age-adjusted anthropometric data for the EF, SF, and BFR groups. *BFR significantly different from EF + SF, P , 0.05. BFR, breastfed reference; EF, experimental formula; SF, standard formula.
TABLE 5
Outcomes for the EF, SF, and BFR groups 1 BFR, breastfed reference; EF, experimental formula; SF, standard formula. 2 Adjusted for maternal and paternal BMI, smoking and chronic disease, maternal weight gain during pregnancy, and gestational diabetes. 3 Comparisons by independent-samples t test. 4 Mean 6 SD (all such values). 5 Not normally distributed, presented as geometric means (95% CIs).
self-regulation. It was shown by Fomon et al (49) , in the 1970s, that infants fed a formula with a very-low energy density (36 kcal/ 100 mL) had higher formula intakes but still less weight gain compared with infants fed an SF (67 kcal/100 mL). In another study by the same group, it was shown that infants fed a formula with very high energy density (100 kcal/100 mL) had lower intakes but still higher weight gains than did infants fed a lowenergy formula (54 kcal/100 mL) (50) . These studies show that self-regulation exists but may not fully compensate for very-low or very-high energy densities. To what degree formula-fed infants can self-regulate intake to compensate for more modest differences in energy density (ie, from 66 to 60 kcal/100 mL), which is in the range of human milk, has been unclear. Several studies have suggested that bottle-fed infants, compared with breastfed infants, have a different pattern of feeding and poor capacity of self-regulation of intake (40, 41, (51) (52) (53) (54) (55) . Compared with the BFR group, the formula-fed infants had faster weight and length gains between inclusion and 6 mo of age. Note that all 3 groups had a linear growth and head circumference slightly over the WHO standards, probably because of differences in population characteristics compared with the WHO reference population and in line with recently published Scandinavian data (56) . Many previous studies have shown faster weight gains in formula-fed infants, more pronounced than in the current study, than in breastfed infants, with higher weight apparent at 6 mo of age (18, 19) . More recent studies on formulas with a proteinenergy ratio reduced to 1.8 g/100 kcal have, in line with our findings, shown more modest differences in growth patterns (57) (58) (59) , which supports the hypothesis that the protein-energy ratio is crucial for weight gain. Plasma insulin and BUN concentrations were higher in the formula-fed than in the breastfed infants, which indicates a higher protein intake for formula-fed infants, well in line with previous findings (60) (61) (62) , which may explain the small difference in growth pattern that still remains. This suggests that there is still room for further reduction in the protein-energy ratio, although such formulas need to be tested in clinical trials.
The contents of essential and conditionally essential amino acids in both the EF and SF groups met the directives of the European Union (33) . A slightly different amino acid composition in the EF group than in the SF group resulted in small but statistically significant differences in plasma amino acid concentrations at 4 mo of age. Proline and glutamic acid were the only amino acids that were lower in the EF group than in the BFR group at 4 mo. They are both nonessential amino acids and share a common carbon backbone and are metabolized via the same pathway; hence, the plasma concentrations mirror a lower intake of both glutamic acid and proline in the EF group.
Some differences between the formula-fed groups and the BFR group (eg, in insulin and BUN concentrations), were observed already at baseline. This was probably caused by the fact that all infants in the EF and SF groups had a period of formula feeding before inclusion. Because exclusive formula-feeding was an inclusion criterion, to avoid affecting the duration of partial breastfeeding in a negative way, only parents of infants who already were exclusively formula-fed were asked to participate in the study. Most parents in all 3 study groups chose to introduce complementary foods between 4 and 6 mo. This dilution of the intervention was a weakness of the study, which led to an underestimation of the biological effect of the nutritional intervention, but, together with calculations on an intent-to-treat basis, gives a picture of the effect in a population.
Another limitation of the study was the double intervention with reductions in both protein and energy contents and supplementation with MFGM, with 2 primary outcomes. The study was designed as such for economical and resource reasons. We predicted that any effect on growth would be caused by the changed energy and protein contents and that any effect on neurodevelopment would be caused by the MFGM supplementation. Because the EF group upregulated their ingested volumes, resulting in similar energy and protein intakes for both formula groups, the probability that the energy or protein intervention had an effect on neurodevelopmental outcomes is low. We cannot, however, exclude an effect of the MFGM on growth or intake.
In conclusion, we found a positive effect of MFGM supplementation of infant formula on cognitive function. In our study population, this nutritional intervention eradicated the gap in cognitive performance between breastfed and formula-fed infants at 12 mo of age. If confirmed by other studies, the results may be of considerable importance for future improvements of infant formulas. A long-term follow-up on cognitive function with a new assessment close to school age would be desirable to find out if the difference between the formula groups persists. Furthermore, formula-fed infants had the capacity to compensate for a reduction of energy density from 66 to 60 kcal/100 mL by increasing ingested volumes. Irrespective of formula composition, insulin and BUN concentrations remained higher in the formula-fed infants than in breastfed infants, which indicated a higher total protein intake. Formula-fed infants also showed slightly accelerated weight and length gains compared with the BFR group until 6 mo of life. Long-term consequences of this are unknown. A long-time follow-up of growth and metabolic status is needed to further elucidate any later differences due to possible programming effects of this nutritional intervention.
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